Kołtowski, Łukasz <br/><br/>
Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773).  [electronic resource] 

 -  Kardiologia polska  2016 
 - 372-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1897-4279 
<br/><br/><label>Standard No.: </label>10.5603/KP.a2015.0172  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Clopidogrel<br/>Cytochrome P-450 CYP2C19--genetics<br/>Humans<br/>Middle Aged<br/>Myocardial Infarction--drug therapy<br/>Percutaneous Coronary Intervention--adverse effects<br/>Pharmacogenomic Testing<br/>Pharmacogenomic Variants<br/>Platelet Aggregation Inhibitors--metabolism<br/>Platelet Function Tests<br/>Prasugrel Hydrochloride--metabolism<br/>Prospective Studies<br/>Research Design<br/>Ticlopidine--analogs & derivatives<br/>Young Adult